Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Work In Process: 2023-2024

Historic Work In Process for Seres Therapeutics (MCRB) over the last 1 years, with Jun 2024 value amounting to $48.1 million.

  • Seres Therapeutics' Work In Process rose 911.85% to $48.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $48.1 million, marking a year-over-year increase of 911.85%. This contributed to the annual value of $25.2 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Seres Therapeutics reported Work In Process of $48.1 million as of Q2 2024, which was up 28.98% from $37.3 million recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' Work In Process registered a high of $48.1 million during Q2 2024, and its lowest value of $4.8 million during Q2 2023.
  • In the last 2 years, Seres Therapeutics' Work In Process had a median value of $25.2 million in 2023 and averaged $26.1 million.
  • Data for Seres Therapeutics' Work In Process shows a peak YoY skyrocketed of 911.85% (in 2024) over the last 5 years.
  • Seres Therapeutics' Work In Process (Quarterly) stood at $25.2 million in 2023, then soared by 911.85% to $48.1 million in 2024.
  • Its last three reported values are $48.1 million in Q2 2024, $37.3 million for Q1 2024, and $25.2 million during Q4 2023.